Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

641. Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department?

Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department? BestBets: Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department? Are beta-blockers superior and safer to digoxin for rate control of acute atrial fibrillation in the emergency department? Report By: Martin Hossack - Medical Student Search checked by Rick Body - Specialist Registrar Institution: Manchester (...) Royal Infirmary Date Submitted: 7th July 2008 Date Completed: 9th January 2009 Last Modified: 14th November 2008 Status: Green (complete) Three Part Question In [patients presenting to the Emergency Department with atrial fibrillation requiring rate limitation] are [beta blockers superior in efficacy and safety to digoxin] in [achieving rate control]? Clinical Scenario A 60 year old man comes to the Emergency Department with symptoms of palpitations. ECG recording confirms atrial fibrillation

BestBETS2009

642. The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter

The Efficacy of Administration of Intravenous Magnesium Sulfate for Improved Ventricular Rate Control or Rhythm Control in Patients with Non-postoperative Atrial Fibrillation and Atrial Flutter "The Efficacy of Administration of Intravenous Magnesium Sulfate for Im" by Mary Schindeler < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers MS, PA-C Second Advisor Rob Rosenow (...) PharmD, OD Rights . Abstract INTRODUCTION: Standard treatment for atrial tachyarrthmias, such as atrial fibrillation or atrial flutter, involves rate and rhythm control. Previous studies have looked at the electrophysiologic effects of magnesium on impulse formation and propagation, and theorized it could be beneficial in treatment for atrial tachycardias. There recently have been studies about magnesium sulfate and its utility in establishing rate and rhythm control in patients

Pacific University EBM Capstone Project2009

643. Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Prophylaxis Post Coronary Artery Bypass Graft Surgery?

Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Prophylaxis Post Coronary Artery Bypass Graft Surgery? "Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Pro" by Felipson Ramos < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS, PA-C Rights . Abstract Background (...) : Atrial Fibrillation (AF) is the most common arrhythmia post Coronary Artery Bypass Graft surgery (CABG). Up to 50% of patients who undergo a CABG procedure will have AF. Metoprolol, a conventional beta-blocker, has been the drug of choice for AF prophylaxis. Sotalol, also a beta-blocker, with class III antiarrythmic effects, could possibly provide a better prophylaxis intervention of AF post CABG surgery. Methods: The focus of this study was to review clinical trials on the comparison between sotalol

Pacific University EBM Capstone Project2009

644. Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibrillation or Long-term Maintenance of Sinus Rhythm Once Cardioversion Has Been Achieved

Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibrillation or Long-term Maintenance of Sinus Rhythm Once Cardioversion Has Been Achieved "Amiodarone as a First-Line Therapy for the Conversion of Atrial Fibril" by Nicole Marie Dwyer < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS (...) , PA-C Rights This work is licensed under a . Abstract Background: Optimal, long-term drug strategies for cardioversion of atrial fibrillation (AF) and maintenance of sinus rhythm (SR) have been controversial. Amiodarone is an old drug that is an effective class III antiarrhythmic for both converting and maintaining sinus rhythm in patients with atrial fibrillation, however, there have been few recent, blinded, randomized controlled studies comparing amiodarone to other pharmacological agents

Pacific University EBM Capstone Project2009

645. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study

Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study 19029470 2008 12 09 2009 01 07 2009 09 17 1524-4539 118 24 2008 Dec 09 Circulation Circulation Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. 2498-505 10.1161/CIRCULATIONAHA.108.772582 The mainstay of treatment for atrial fibrillation (AF) remains pharmacological; however, catheter ablation has increasingly been used over the last decade. The relative merits of each strategy (...) have not been extensively studied. We conducted a randomized multicenter comparison of these 2 treatment strategies in patients with paroxysmal AF resistant to at least 1 antiarrhythmic drug. The primary end point was absence of recurrent AF between months 3 and 12, absence of recurrent AF after up to 3 ablation procedures, or changes in antiarrhythmic drugs during the first 3 months. Ablation consisted of pulmonary vein isolation in all cases, whereas additional extrapulmonary vein lesions were

EvidenceUpdates2009

646. Valsartan for prevention of recurrent atrial fibrillation.

Valsartan for prevention of recurrent atrial fibrillation. 19369667 2009 04 16 2009 04 20 2015 11 19 1533-4406 360 16 2009 Apr 16 The New England journal of medicine N. Engl. J. Med. Valsartan for prevention of recurrent atrial fibrillation. 1606-17 10.1056/NEJMoa0805710 Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling (...) , and some clinical studies suggest that they may prevent atrial fibrillation. We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had

NEJM2009

647. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. 19336502 2009 05 14 2009 05 19 2013 11 21 1533-4406 360 20 2009 May 14 The New England journal of medicine N. Engl. J. Med. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. 2066-78 10.1056/NEJMoa0901301 Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated (...) the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation. A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin. The primary outcome was the composite of stroke, myocardial infarction, non-central nervous system systemic embolism, or death

NEJM2009

648. Dabigatran versus warfarin in patients with atrial fibrillation.

Dabigatran versus warfarin in patients with atrial fibrillation. 19717844 2009 09 17 2009 09 23 2015 11 19 1533-4406 361 12 2009 Sep 17 The New England journal of medicine N. Engl. J. Med. Dabigatran versus warfarin in patients with atrial fibrillation. 1139-51 10.1056/NEJMoa0905561 Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this noninferiority trial (...) , we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran

NEJM2009

649. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. 19683639 2009 08 17 2009 08 27 2015 06 16 1474-547X 374 9689 2009 Aug 15 Lancet (London, England) Lancet Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. 534-42 10.1016/S0140-6736(09)61343-X In patients (...) with non-valvular atrial fibrillation, embolic stroke is thought to be associated with left atrial appendage (LAA) thrombi. We assessed the efficacy and safety of percutaneous closure of the LAA for prevention of stroke compared with warfarin treatment in patients with atrial fibrillation. Adult patients with non-valvular atrial fibrillation were eligible for inclusion in this multicentre, randomised non-inferiority trial if they had at least one of the following: previous stroke or transient ischaemic

Lancet2009

650. Effect of dronedarone on cardiovascular events in atrial fibrillation.

Effect of dronedarone on cardiovascular events in atrial fibrillation. 19213680 2009 02 13 2009 02 19 2013 11 21 1533-4406 360 7 2009 Feb 12 The New England journal of medicine N. Engl. J. Med. Effect of dronedarone on cardiovascular events in atrial fibrillation. 668-78 10.1056/NEJMoa0803778 Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation. We conducted a multicenter trial to evaluate the use of dronedarone in 4628 patients (...) with atrial fibrillation who had additional risk factors for death. Patients were randomly assigned to receive dronedarone, 400 mg twice a day, or placebo. The primary outcome was the first hospitalization due to cardiovascular events or death. Secondary outcomes were death from any cause, death from cardiovascular causes, and hospitalization due to cardiovascular events. The mean follow-up period was 21+/-5 months, with the study drug discontinued prematurely in 696 of the 2301 patients (30.2%) receiving dronedarone

NEJM2009

651. Alcohol consumption and risk of incident atrial fibrillation in women.

Alcohol consumption and risk of incident atrial fibrillation in women. CONTEXT: Previous studies suggest that consuming moderate to high amounts of alcohol on a regular basis might increase the risk of developing atrial fibrillation in men but not in women. However, these studies were not powered to investigate the association of alcohol consumption and atrial fibrillation among women. OBJECTIVE: To prospectively assess the association between regular alcohol consumption and incident (...) atrial fibrillation among women. DESIGN, SETTING, AND PARTICIPANTS: Participants were 34 715 initially healthy women participating in the Women's Health Study, a completed randomized controlled trial conducted in the United States. Participants were older than 45 years and free of atrial fibrillation at baseline and underwent prospective follow-up from 1993 to October 31, 2006. Alcohol consumption was assessed via questionnaires at baseline and at 48 months of follow-up and was grouped into 4 categories (0, >

JAMA2008 Full Text: Link to full Text with Trip Pro

652. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation

Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2008

653. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study

High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study 19001198 2008 11 12 2008 12 01 2013 11 21 1538-3679 168 20 2008 Nov 10 Archives of internal medicine Arch. Intern. Med. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. 2219-24 10.1001/archinte.168.20.2219 Overt and subclinical hyperthyroidism are both well-known independent risk factors for atrial fibrillation. We aimed to investigate the association of high-normal thyroid (...) function with the development of atrial fibrillation in a prospective population-based study in the elderly. The association between thyroid-stimulating hormone (TSH) levels and atrial fibrillation was examined in 1426 subjects with TSH levels in the normal range (0.4-4.0 mU/L) and without atrial fibrillation at baseline. In 1177 of the 1426 persons in this group, we also examined the association between free thyroxine levels within the normal range (0.86-1.94 ng/dL [to convert to picomoles per liter

EvidenceUpdates2008

654. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery

Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery 18824641 2008 10 14 2008 11 14 2016 12 15 1524-4539 118 16 2008 Oct 14 Circulation Circulation Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. 1619-25 10.1161/CIRCULATIONAHA.108.790162 Postoperative atrial fibrillation (AF), a frequent complication after cardiac surgery, causes morbidity and prolongs hospitalization. Inotropic drugs are commonly used perioperatively (...) to support ventricular function. This study tested the hypothesis that the use of inotropic drugs is associated with postoperative AF. We evaluated perioperative risk factors in 232 patients who underwent elective cardiac surgery. All patients were in sinus rhythm at surgery. Sixty-seven patients (28.9%) developed AF a mean of 2.9+/-2.1 days after surgery. Patients who developed AF stayed in the hospital longer (P<0.001) and were more likely to die (P=0.02). Milrinone use was associated with an increased

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

655. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years

Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years 18611964 2008 09 15 2008 11 13 2016 11 24 1522-9645 29 18 2008 Sep European heart journal Eur. Heart J. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. 2227-33 10.1093/eurheartj/ehn324 Obesity has been shown to be a risk factor for first atrial fibrillation (AF), but whether (...) it is associated with progression from paroxysmal to permanent AF is unknown. In this longitudinal cohort study, Olmsted County, MN residents confirmed to have developed paroxysmal AF during 1980-2000 were identified and followed passively to 2006. The interrelationships of body mass index (BMI), left atrial (LA) size, and progression to permanent AF were analysed. Of a total of 3248 patients (mean age 71 +/- 15 years; 54% men) diagnosed with paroxysmal AF, 557 (17%) progressed to permanent AF (unadjusted

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

656. A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation

A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation 18339449 2008 09 23 2008 10 07 2009 04 21 1097-6760 52 4 2008 Oct Annals of emergency medicine Ann Emerg Med A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation. 322-8 10.1016/j.annemergmed.2007.12.015 An emergency department (ED) observation unit protocol for the management of acute onset atrial fibrillation is compared (...) with routine hospital admission and management. Adult patients presenting to the ED with atrial fibrillation of less than 48 hours' duration without hemodynamic instability or other comorbid conditions requiring hospitalization were enrolled. Participants were randomized to either ED observation unit care or routine inpatient care. The ED observation unit protocol included pulse rate control, cardiac monitoring, reassessment, and electrical cardioversion if atrial fibrillation persisted. Patients who

EvidenceUpdates2008

657. Does sodium nitroprusside decrease the incidence of atrial fibrillation after myocardial revascularization?

Does sodium nitroprusside decrease the incidence of atrial fibrillation after myocardial revascularization? 18625896 2008 07 29 2008 08 20 2013 11 21 1524-4539 118 5 2008 Jul 29 Circulation Circulation Does sodium nitroprusside decrease the incidence of atrial fibrillation after myocardial revascularization?: a pilot study. 476-81 10.1161/CIRCULATIONAHA.107.719377 Atrial fibrillation (AF) often occurs after coronary artery bypass grafting and can result in increased morbidity and mortality (...) . In the present pilot study, our aim was to investigate whether sodium nitroprusside (SNP), as a nitric oxide donor, can reduce the frequency of post-coronary artery bypass grafting AF. To investigate the effectiveness of SNP in the prophylaxis of AF, we conducted a prospective, randomized, placebo-controlled clinical study on 100 consecutive patients in whom we performed elective and initial CABG operations. A control group of 50 patients were treated with placebo (dextrose 5% in water), whereas the SNP

EvidenceUpdates2008

658. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.

Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. Atrial fibrillation is a common arrhythmia that is hereditary in a small subgroup of patients. In a family with 11 clinically affected members, we mapped an atrial fibrillation locus to chromosome 1p36-p35 and identified a heterozygous frameshift mutation in the gene encoding atrial natriuretic peptide. Circulating chimeric atrial natriuretic peptide (ANP) was detected in high concentration in subjects (...) with the mutation, and shortened atrial action potentials were seen in an isolated heart model, creating a possible substrate for atrial fibrillation. This report implicates perturbation of the atrial natriuretic peptide-cyclic guanosine monophosphate (cGMP) pathway in cardiac electrical instability. 2008 Massachusetts Medical Society

NEJM2008 Full Text: Link to full Text with Trip Pro

659. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

NIHR HTA programme2008

660. Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial

Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial 17591649 2008 06 16 2008 10 24 2008 06 16 1468-201X 94 7 2008 Jul Heart (British Cardiac Society) Heart Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. 884-7 To compare the efficacy and safety of an escalating energy protocol with a non-escalating energy protocol using an impedance compensated biphasic defibrillator for direct current (...) cardioversion of atrial fibrillation (AF). This prospective multicentre randomised trial enrolled 380 patients (248 male, mean (SD) age 67 (10) years) with AF. Patients were randomised to either an escalating energy protocol (protocol A: 100 J, 150 J, 200 J, 200 J), or a non-escalating energy protocol (protocol B: 200 J, 200 J, 200 J). Cardioversion was performed using an impedance compensated biphasic waveform. First-shock success was significantly higher for those randomised to 200 J than 100 J (71% vs 48

EvidenceUpdates2008